BACKGROUND: P53 and ATM are central checkpoint genes involved in the repair of DNA damage after ionising irradiation, which has been associated with risk of brain tumours. Therefore, we tested the hypothesis that polymorphisms and haplotypes in p53 and ATM could be associated with glioma and meningioma risk. MATERIAL AND METHODS: Six hundred and eighty glioma cases (298 glioblastoma (GBM)), 503 meningioma cases, and 1555 controls recruited in the Nordic-UK Interphone study, were analysed in association with three polymorphisms in p53 (rs2287499, rs1042533, rs1625895) and five polymorphisms in ATM ( rs228599, rs3092992, rs664143, rs170548, rs3092993). Haplotypes were constructed using the HAPLOSTAT program. RESULTS: The global statistical test of glioblastoma and p53 haplotypes was p = 0.02. The haplotype analysis on glioblastoma revealed the 1-2-2 haplotype (promotor-codon72-intron 6) had a frequency of 6.1% in cases compared with 9.8% in controls (p = 0.003). The 1-2-1 haplotype was significantly more frequent in GBM cases, 10.2%, than in controls, 7.3% (p = 0.02). The haplotype analysis in ATM revealed an increased frequency of the 1-1-1-2-1 haplotype in meningioma cases (33.8%) compared with controls (30.3%) (p = 0.03). The 2-1-2-1-1 haplotype had a lower frequency in meningioma cases (36.1%) than controls (40.7%) (p = 0.009). CONCLUSIONS: This study found both positive and negative associations of haplotypes in p53 for glioblastoma and ATM for meningioma. This study provides new data that could add to our understanding of brain tumour susceptibility.
BACKGROUND: P53 and ATM are central checkpoint genes involved in the repair of DNA damage after ionising irradiation, which has been associated with risk of brain tumours. Therefore, we tested the hypothesis that polymorphisms and haplotypes in p53 and ATM could be associated with glioma and meningioma risk. MATERIAL AND METHODS: Six hundred and eighty glioma cases (298 glioblastoma (GBM)), 503 meningioma cases, and 1555 controls recruited in the Nordic-UK Interphone study, were analysed in association with three polymorphisms in p53 (rs2287499, rs1042533, rs1625895) and five polymorphisms in ATM ( rs228599, rs3092992, rs664143, rs170548, rs3092993). Haplotypes were constructed using the HAPLOSTAT program. RESULTS: The global statistical test of glioblastoma and p53 haplotypes was p = 0.02. The haplotype analysis on glioblastoma revealed the 1-2-2 haplotype (promotor-codon72-intron 6) had a frequency of 6.1% in cases compared with 9.8% in controls (p = 0.003). The 1-2-1 haplotype was significantly more frequent in GBM cases, 10.2%, than in controls, 7.3% (p = 0.02). The haplotype analysis in ATM revealed an increased frequency of the 1-1-1-2-1 haplotype in meningioma cases (33.8%) compared with controls (30.3%) (p = 0.03). The 2-1-2-1-1 haplotype had a lower frequency in meningioma cases (36.1%) than controls (40.7%) (p = 0.009). CONCLUSIONS: This study found both positive and negative associations of haplotypes in p53 for glioblastoma and ATM for meningioma. This study provides new data that could add to our understanding of brain tumour susceptibility.
Authors: José M Ojeda; Sandra Ampuero; Patricio Rojas; Rodrigo Prado; Jorge E Allende; Sara A Barton; Ranajit Chakraborty; Francisco Rothhammer Journal: Biol Res Date: 2003 Impact factor: 5.612
Authors: Sara Lindström; Fredrik Wiklund; Björn-Anders Jonsson; Hans-Olov Adami; Katarina Bälter; Anthony J Brookes; Jianfeng Xu; S Lilly Zheng; William B Isaacs; Jan Adolfsson; Henrik Grönberg Journal: Hum Genet Date: 2005-09-28 Impact factor: 4.132
Authors: Michel H Bourguignon; Pablo A Gisone; Maria R Perez; Severino Michelin; Diana Dubner; Marina Di Giorgio; Edgardo D Carosella Journal: Eur J Nucl Med Mol Imaging Date: 2005-02 Impact factor: 9.236
Authors: Margaret Wrensch; Karl T Kelsey; Mei Liu; Rei Miike; Michelle Moghadassi; Kenneth Aldape; Alex McMillan; John K Wiencke Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-03 Impact factor: 4.254
Authors: Anneclaire J De Roos; Nat Rothman; Peter D Inskip; Martha S Linet; William R Shapiro; Robert G Selker; Howard A Fine; Peter M Black; Gary S Pittman; Douglas A Bell Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-01 Impact factor: 4.254
Authors: J H Olsen; J M D Hahnemann; A-L Børresen-Dale; S Tretli; R Kleinerman; R Sankila; L Hammarström; T E Robsahm; H Kääriäinen; A Bregård; K Brøndum-Nielsen; J Yuen; M Tucker Journal: Br J Cancer Date: 2005-07-25 Impact factor: 7.640
Authors: Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler Journal: Cancer Date: 2008-10-01 Impact factor: 6.860